Efstathios Kastritis, MD: A New Standard of Care for Amyloidosis in Multiple Myeloma?

Posted: Wednesday, July 7, 2021

Efstathios Kastritis, MD, of the University of Athens, discusses updated findings from the phase III ANDROMEDA study and the clinical implications of supplementing the current standard of care for light chain amyloidosis (bortezomib, cyclophosphamide, and dexamethasone) with daratumumab.